Ganoderma lucidum was unveiled at the 16th American Society of Integrated Oncology (SIO) International Conference 2019

the American Society of Integrated Oncology (SIO) was established in 2003 and is the premier nonprofit multidisciplinary comprehensive oncology professional organization. This forum invited doctors, researchers, nutritionists and other scientific health discipline advocates from 20 countries such as MD Anderson Cancer Center, Mayo Clinic, New York Memorial Sloan Kettering Cancer Center (hereinafter referred to as MSKCC) . The three-day conference report focuses on the lifestyle, microbiome and sleep problems of cancer patients, and introduces the findings and progress of cutting-edge international scientific research. It aims to share international comprehensive oncology research, diagnostic techniques, treatment options and best patient practices. At the same time, the forum also invited the world's leading natural medicine manufacturers to participate.     Ganoderma lucidum enters the international stage

Ganoderma lucidum enters the international stage   As a domestic high-quality enterprise in the field of natural herbal medicine, Zhongke Group was invited to appear in this forum with the innovative medicine "Zhongke Compound Ganoderma Spore Capsule". Professor Liu Jie, a visiting scholar from Guanganmen Hospital in the United States, detailed the three-phase randomized, double-blind, placebo-controlled clinical trial study of "Zhongke Compound Ganoderma Spore Capsule" in China at the forum. At the forum, MSKCC announced for the first time to the academic community the results of a preliminary clinical study in the United States that "Zhongke compound ganoderma lucidum spore capsules improve the quality of life and anti-fatigue of patients during chemotherapy of non-small cell lung cancer." The ganoderma products introduced by the institution have received great attention from the academic circles.